NCT03194373View on ClinicalTrials.gov

Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

October 12, 2017

Primary Completion Date

February 1, 2019

Study Completion Date

March 17, 2020

Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
DRUG

Palbociclib

"Palbociclib (Ibrance) (PO), dose= 125 mg PO daily, days=1-14, cycle length: 21 days~Maintenance Palbociclib:~Palbociclib (Ibrance) 125 mg PO daily, days 1-21, cycle length: 28 days"

DRUG

Carboplatin

Carboplatin (IV), dose= AUC 5, day= 1, cycle length: 21 days

Trial Locations (3)

37203

Vanderbilt University, Nashville

46202

Indiana University Simon Cancer Center, Indianapolis

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER

NCT03194373 - Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter